Beneficial Effects Authors Number of Allopurinol Study Subjects     Subjects Dose (mg)   Endothelial Dysfunction           Butler et al. [56] 23 300 Type 2 Diabetes with mild hypertension   Dogan et al. [70] 50 900 Normotensive Type 2 Diabetes   Yiginer et al. [71] 28 300 Metabolic Syndrome   Guthikonda et al. [72] 28 600 Heavy Smokers   George et al. [57] 30 300 to 600 Chronic heart failure   Kanbay et al. [73] 67 300 Asymptomatic hyperuricemia and normal renal function           Proteinuria           Momeni et al. [74] 40 100 Type 2 Diabetes           Cardiovascular System         Myocardial efficiency Cappola et al. [75] 9 - Idiopathic dilated cardiomyopathy Postoperative Recovery Coghlan et al. [76] 50 - Undergoing coronary artery bypass grafting Peripheral blood flow Doehner et al. [77] 19 300 Hyperuricemic subjects with chronic heart failure Endothelial progenitor cells Tousoulis et al. [78] 60 300 Congestive heart failure Vascular and functional parameters Greig et al. [79] 74 300 Chronic heart failure Cardiovascular autonomic neuropathy and Myocardial blood flow       Type 1 Diabetes Left ventricular mass Rekhraj et al. [80] 66 600 Ischemic heart disease   Szwejkowski et al. [81] 66 600 Type 2 Diabetes and left ventricular hypertrophy           Cerebrovascular System         Nitric oxide activity Dawson et al. [82] 14 300 Type 2 Diabetes Blood pressure and carotid intima-media thickness Higgins et al. [83] 80 300 Post ischemic stroke and transient ischemic attack Inflammatory markers Muir et al. [84] 50 100-300 Recent ischemic stroke           Chronic Kidney Disease (CKD)         CKD progression and Cardiovascular risk Goicoechea et al. [85] 113 100 CKD with and without Diabetes Endothelial Dysfunction and Left ventricular hypertrophy Kao et al. [86] 67 300 CKD

Table 1: Beneficial effects of Allopurinol in Human Subjects.